Blueprint Medicines Corp Stock Analysis
| BPMC Stock | USD 93.08 2.19 2.30% |
Blueprint Medicines Corp is undervalued with Real Value of 104.74 and Hype Value of 91.47. The main objective of Blueprint Medicines stock analysis is to determine its intrinsic value, which is an estimate of what Blueprint Medicines Corp is worth, separate from its market price. There are two main types of Blueprint Medicines' stock analysis: fundamental analysis and technical analysis.
The Blueprint Medicines stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Blueprint Medicines' ongoing operational relationships across important fundamental and technical indicators.
Blueprint |
Blueprint Stock Analysis Notes
About 99.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 1.07. Blueprint Medicines Corp had not issued any dividends in recent years. Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. Blueprint Medicines operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 580 people. For more info on Blueprint Medicines Corp please contact Kathryn MBA at (617) 374-7580 or go to https://www.blueprintmedicines.com.Blueprint Medicines Corp Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Blueprint Medicines' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Blueprint Medicines Corp or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Blueprint Medicines had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 508.82 M. Net Loss for the year was (67.09 M) with profit before overhead, payroll, taxes, and interest of 488.66 M. | |
| Blueprint Medicines Corp currently holds about 853.11 M in cash with (192.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.28. | |
| Blueprint Medicines has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies |
Blueprint Medicines Corp Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Blueprint Medicines previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Blueprint Medicines Thematic Classifications
In addition to having Blueprint Medicines stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | Cancer FightersPublic companies from health care and pharmaceutical sectors that are focused on fighting cancer |
Blueprint Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.09 B.Blueprint Profitablity
The company has Profit Margin (PM) of (0.13) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.28) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.28.Technical Drivers
As of the 26th of March, Blueprint Medicines shows the Risk Adjusted Performance of 0.0184, downside deviation of 2.61, and Mean Deviation of 2.28. Blueprint Medicines Corp technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Blueprint Medicines Corp Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Blueprint Medicines middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Blueprint Medicines Corp. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Blueprint Medicines Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Blueprint Medicines insiders, such as employees or executives, is commonly permitted as long as it does not rely on Blueprint Medicines' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Blueprint Medicines insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Blueprint Medicines Outstanding Bonds
Blueprint Medicines issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Blueprint Medicines Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Blueprint bonds can be classified according to their maturity, which is the date when Blueprint Medicines Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US09624HAA77 Corp BondUS09624HAA77 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Blueprint Medicines Predictive Daily Indicators
Blueprint Medicines intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Blueprint Medicines stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Blueprint Medicines Forecast Models
Blueprint Medicines' time-series forecasting models are one of many Blueprint Medicines' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Blueprint Medicines' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Blueprint Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Blueprint Medicines prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Blueprint shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Blueprint Medicines. By using and applying Blueprint Stock analysis, traders can create a robust methodology for identifying Blueprint entry and exit points for their positions.
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. Blueprint Medicines operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 580 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Blueprint Medicines to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Center Now
Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios |
| All Next | Launch Module |
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |